Orforglipron

capsuleOral

First oral non-peptide GLP-1 agonist in late-stage trials. A daily pill alternative to injectable GLP-1s with promising early weight loss data.

Key Facts

Classification
Capsule — First oral non-peptide GLP-1 agonist in late-stage trials.
Primary Benefits
Fat Loss (9/10) · Gut Health (3/10)
Administration
Oral
Typical Dose
12-36-120 mg oral daily in the morning. Titrate up gradually.
Evidence Strength
Emerging · Community sentiment 8/10

Quick Facts

From price: N/A
Type: capsule
Administration: Oral
Evidence: emerging
Studies referenced: 0
Community sentiment: 8/10
Stacks with: 0 peptides

Dosing

12-36-120 mg oral daily in the morning. Titrate up gradually.

Benefit Profile

🔥 Fat Loss

9/10

🫃 Gut Health

3/10